Abstract
COVID-19 disease was spread rapidly on a global scale. Corticosteroids were believed to reduce the inflammatory lung injury, however, its side effects include increased secondary infections, immunomodulation, and manifestation of latent diabetes mellitus. The incidence of mucormycosis infection was high in post COVID-19-infected patients. Mucormycosis of femur in patients of post-COVID-19 infection was extremely rare and not yet reported. We report a case of COVID-19 recovered patient with mucormycosis of right distal femur, who underwent 18Ffluorodeoxyglucose (18FFDG) positron emission tomography/computed tomography (PET/CT) for additional sites of disease. This case highlights potential of 18FFDG PET/CT in the management of mucormycosis.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
